Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Exelixis Inc (EXEL)  
$20.49 0.15 (0.74%) as of 4:30 Wed 5/29


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 310,240,000
Market Cap: 6.36(B)
Last Volume: 1,870,637 Avg Vol: 2,436,577
52 Week Range: $18.78 - $24.13
Level I Sector: Industrials
Level II Sector: Diversified Services
Level III Sector: Research Services

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 14.9
Insider 3/6 Months : 15.5
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 190,000 310,409 310,409
Total Buy Value $0 $3,932,734 $6,534,772 $6,534,772
Total People Bought 0 1 1 1
Total Buy Transactions 0 1 2 2
Total Shares Sold 80,531 266,700 593,372 1,012,962
Total Sell Value $1,755,807 $5,927,239 $12,725,795 $20,083,859
Total People Sold 5 7 9 12
Total Sell Transactions 5 11 16 27
End Date 2024-02-29 2023-11-28 2023-05-30 2022-05-30

   
Records found: 1426
  Page 1 of 58  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Poste George Director   –       •      –    2024-05-21 4 S $20.96 $244,939 D/D (11,686) 213,907 3%     
   Poste George Director   –       •      –    2024-05-21 4 OE $19.57 $228,695 D/D 11,686 225,593     -
   Smith Julie Director   –       •      –    2024-05-21 4 S $21.12 $576,154 D/D (27,280) 5,445 3%     
   Papadopoulos Stelios Director   –       •      –    2024-05-20 4 S $21.00 $240,177 D/D (11,437) 1,260,578 3%     
   Papadopoulos Stelios Director   –       •      –    2024-05-20 4 OE $19.57 $228,695 D/D 11,686 1,272,015     -
   Senner Christopher J. EVP and CFO   •       –      –    2024-05-15 4 D $20.99 $636,207 D/D (30,310) 721,680     -
   Morrissey Michael M President and CEO   •       •      –    2024-05-15 4 D $20.99 $1,552,064 D/D (73,943) 964,384     -
   Aftab Dana CSO/EVP Disc & Trans Research   •       –      –    2024-05-15 4 D $20.99 $474,479 D/D (22,605) 520,990     -
   Haley Patrick J. EVP, Commercial   •       –      –    2024-05-15 4 D $20.99 $651,614 D/D (31,044) 355,036     -
   Hessekiel Jeffrey EVP, General Counsel & Sec   •       –      –    2024-05-15 4 D $20.99 $544,502 D/D (25,941) 630,325     -
   Wyszomierski Jack L Director   –       •      –    2024-05-13 4 AS $21.37 $233,425 D/D (10,923) 338,948 -3%     
   Wyszomierski Jack L Director   –       •      –    2024-05-13 4 OE $19.57 $228,695 D/D 11,686 349,871     -
   Garber Alan M Director   –       •      –    2024-03-21 4 AS $24.01 $461,112 D/D (19,205) 35,703 -14%     
   Garber Alan M Director   –       •      –    2024-03-21 4 OE $19.57 $459,719 D/D 23,491 54,908     -
   Haley Patrick J. EVP, Commercial   •       –      –    2024-02-23 4 S $21.45 $1,008,579 D/D (47,020) 384,866 5%     
   Haley Patrick J. EVP, Commercial   •       –      –    2024-02-23 4 A $0.00 $0 D/D 63,350 431,886     -
   Morrissey Michael M President and CEO   •       •      –    2024-02-23 4 A $0.00 $0 D/D 241,670 1,038,327     -
   Peterson Amy C. EVP Prod Dev & Med Aff & CMO   •       –      –    2024-02-23 4 A $0.00 $0 D/D 82,121 322,121     -
   Senner Christopher J. EVP and CFO   •       –      –    2024-02-23 4 A $0.00 $0 D/D 82,121 751,990     -
   Hessekiel Jeffrey EVP, General Counsel & Sec   •       –      –    2024-02-23 4 A $0.00 $0 D/D 63,350 655,052     -
   Aftab Dana CSO/EVP Disc & Trans Research   •       –      –    2024-02-23 4 A $0.00 $0 D/D 63,350 542,381     -
   Caligan Partners Lp See Remarks   –       •      –    2024-02-21 4 B $20.70 $3,932,734 I/I 190,000 1,100,730 2.1 -1%     
   Aftab Dana CSO/EVP Disc & Trans Research   •       –      –    2024-02-15 4 D $20.39 $216,746 D/D (10,630) 479,031     -
   Haley Patrick J. EVP, Commercial   •       –      –    2024-01-11 4 D $22.86 $311,193 D/D (13,613) 368,536     -
   Haley Patrick J. EVP, Commercial   •       –      –    2024-01-11 4 A $0.00 $0 D/D 74,462 382,149     -
  1426 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 58
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us